|
COPYRIGHT 2003 International Medical News Group
SEVILLE, SPAIN -- Extracorporeal photophoresis has shown promise as an adjunctive immunosuppressive treatment, but its efficacy must still be proved in large-scale trials.
The treatment, which uses a blood-separation protocol plus UV radiation to inactivate a patient's leukocytes, has been successfully applied to cutaneous T-cell lymphoma, atopic dermatitis, rejection of solid organ transplants, and graft-vs-host disease (GVHD).
The regimen has been both strikingly effective and devoid of significant adverse effects. But all of the study results reported so far have come from series or small controlled studies.
"All of the applications need large, multicenter, randomized, placebo-controlled trials," Dr. Robert Knobler said at the Ninth...
Read the full article for free courtesy of your local library.
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
